Q 12: In children and adolescents with anxiety disorders, what is the effectiveness and safety, considering system issues in low- and middle-income countries, of using pharmacological interventions in non-specialist settings?
54th directing council; 67th session of the regional Committee of WHO for the Americas
CD54/11, Rev. 1, 2 October 2015, Original: Spanish
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 11, November 2017
Child Survival Working Group
Accessed: 26.10.2019
14 June 2022.
The aim of this document is to provide concise advice to public health authorities and guide their prevention, awareness-raising and behaviour change interventions before, during and after upcoming summer events.
Q3: Are pharmacotherapies safe and effective for the treatment of psychostimulant dependence (maintenance or relapse prevention) in non-specialized settings?
When Ebola hit Liberia in 2014, an atmosphere of fear and confusion contributed to the spread of the virus by making people unwilling to come forward for testing and treatment. Oxfam trained and equipped community health volunteers to go door-to-door, giving information and advice, encouraging anyon...e showing symptoms to go for tests, and keeping their family members informed about the progress of their treatment. The approach won the trust of communities and helped to slow the spread of the disease. This case study gives an overview of the programme, including aims, results and a personal story.
more
Tackling Tuberculosis in Under-Served Populations: A Resource for TB Control Boards and their partners
CBDRR Practice. Case Studies 3
No publication year indicated.
Guide to access the National AMR Surveillance Dashboard
Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
A Summary
Accessed: 23.11.2019